Briacell Therapeutics CORP (BCTXL) Hedge Fund & Institutional Holdings (Q2 2026)

BCTXL ranks #10070 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

BCTXL is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

10 institutions disclose a position in BCTXL, but none treat it as a major bet — even Empery Asset Management, LP, its most concentrated holder, allocates just 0.3% of its own portfolio to it.

BCTXL reported a net loss of $26.3M in its latest fiscal year.

• Not yet profitable — net loss of $26.3M in the latest fiscal year
• Net income declined year over year, from -$4.8M to -$26.3M
• Operating cash flow was negative, using $28.2M in cash
• Current ratio of 5.01x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.21x equity — within a conventional range